Aardvark Therapeutics (AARD) Change in Accured Expenses (2024 - 2026)

Aardvark Therapeutics has reported Change in Accured Expenses for 3 years, with the latest figure at -$1.3 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 189.36% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 million (up 62.12% YoY) and the FY2025 annual result came in at $6.4 million, up 363.18% from the prior year.
• Change in Accured Expenses retreated to -$1.3 million in Q1 2026 per AARD's latest filing, from $2.2 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $2.2 million in Q4 2025 and troughed at -$1.3 million in Q1 2026.
• A 3-year average of $726666.7 and a median of $614000.0 in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses jumped 72500.0% in 2025, then sank 189.36% in 2026.
• Over 3 years, Change in Accured Expenses stood at -$3000.0 in 2024, then surged by 72500.0% to $2.2 million in 2025, then tumbled by 158.01% to -$1.3 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$1.3 million, $2.2 million, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.